Search - tctmd.com

Displaying 341 - 360 of 378

Presentation TCT 2013

Coronary Endothelial Dysfunction Predicts Long-term Prognosis In Patients With Successful First Generation Drug-eluting Stents Implantation Without Residual Stenosis At Chronic...

Presenter: Shigenori Ito, Kosuke Nakasuka, Satoru Sekimoto, Kazuyuki Miyata, Masahiko Inomata, Takayuki Yoshida, Nozomu Tamai, Tomoaki Saeki, Shin Suzuki, Yoshimasa Murakami, Koichi Sato

January 31, 2013

Presentation TCT 2013

Below-Knee Drug Eluting Stents Have Improved Patency, and Symptoms Compared to Bare Metal Stents: a meta-analysis

Presenter: Alexandre Benjo, Francisco Macedo, Emad Aziz, Francisco Nascimento, Fahad Javed, Eyal Herzog, Tyrone Collins, Christopher White

January 31, 2013

Presentation

BELLO: Paclitaxel Drug-Eluting Balloons vs. Paclitaxel-Eluting Stents in Small Coronary Vessels

Presenter: A. Latib

November 13, 2012

Presentation TCT 2012

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

Presenter: Antonio Colombo

October 26, 2012

Presentation TCT 2012

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

Presenter: Dean Kereiakes

October 25, 2012

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

Presentation TCT 2012

TCT-75. Lumen Enlargement of the Coronary Segments Located Distal to Chronic Total Occlusions Successfully Treated with Drug-Eluting Stents at Follow-up

Presenter: Josep Gomez-Lara

October 23, 2012

Presentation TCT 2012

Bare Metal vs. Drug-Eluting Stents: Mechanisms of Action and Comparative Effectiveness and Safety

Presenter: Ajay Kirtane

October 23, 2012

Presentation TCT 2012

Progress with Drug-Eluting Magnesium Resorbing Stents (BIOTRONIK): DREAMS 2-Year Results

Presenter: Michael Haude

October 23, 2012

Presentation TCT 2012

After CTO Recanalization, What Is the Role of Drug-Eluting Devices, Covered Stents, Etc?

Presenter: Thomas Zeller

October 23, 2012

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Presenter: Gary Ansel

October 22, 2012

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

Presenter: Lawrence Garcia

October 22, 2012

Presentation

Changes to Polymer Surface of Drug-Eluting Stents During Balloon Expansion

Presenter: 167498|Scott Denardo

May 24, 2012

Presentation Fellows 2012

Next-Generation Technologies: Bioabsorbable Stents/Polymers, Drug-Eluting Balloons, and More

Presenter: Juan Granada

April 21, 2012

Presentation Fellows 2012

First-Generation Drug-Eluting Stents: The Good, the Bad, and the Ugly

Presenter: Issam Moussa

April 21, 2012

Presentation ACC 2012

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Presenter: Robert A. Byrne

March 24, 2012

Presentation PCI Outcomes 2012

Controversy 1: Current Drug-Eluting Stents Are Not Only More Effective But Are Safer Than Bare Metal Stents and Should Be Used in more than 90% of (Stented) Patients

Presenter: Gregg W. Stone

March 23, 2012

Presentation TCT 2012

Tissue coverage and neointimal hyperplasia of overlap vs. non-overlap segments in drug-eluting stents 9-13 months after implantation: in vivo-assessment with optical coherence...

Presenter: Juan Luis Guti?rrez-Chico, Lorenz R?ber, Evelyn Regar, Takayuki Okamura, Carlo di Mario, Stephan Windecker, Gerrit-Anne van Es, Patrick W. Serruys

January 03, 2012

Presentation TCT 2012

The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON) Compared with Different Polymer Based Drug-Eluting Stents in Real-World Coronary Artery Lesions.

Presenter: Ted S. Trajceski, Lulzim Brovina, Zivko Petrovski, Blerim Zuna, Borce Petrovski

January 03, 2012

Presentation TCT 2012

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Presenter: Israel M. Barbash, Rebecca Torgusson, Itsik Ben-Dor, Gabriel Maluenda, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

January 03, 2012

Advertisement

Coronary Endothelial Dysfunction Predicts Long-term Prognosis In Patients With Successful First Generation Drug-eluting Stents Implantation Without Residual Stenosis At Chronic...

Below-Knee Drug Eluting Stents Have Improved Patency, and Symptoms Compared to Bare Metal Stents: a meta-analysis

BELLO: Paclitaxel Drug-Eluting Balloons vs. Paclitaxel-Eluting Stents in Small Coronary Vessels

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

TCT-75. Lumen Enlargement of the Coronary Segments Located Distal to Chronic Total Occlusions Successfully Treated with Drug-Eluting Stents at Follow-up

Bare Metal vs. Drug-Eluting Stents: Mechanisms of Action and Comparative Effectiveness and Safety

Progress with Drug-Eluting Magnesium Resorbing Stents (BIOTRONIK): DREAMS 2-Year Results

After CTO Recanalization, What Is the Role of Drug-Eluting Devices, Covered Stents, Etc?

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

Changes to Polymer Surface of Drug-Eluting Stents During Balloon Expansion

Next-Generation Technologies: Bioabsorbable Stents/Polymers, Drug-Eluting Balloons, and More

First-Generation Drug-Eluting Stents: The Good, the Bad, and the Ugly

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Controversy 1: Current Drug-Eluting Stents Are Not Only More Effective But Are Safer Than Bare Metal Stents and Should Be Used in more than 90% of (Stented) Patients

Tissue coverage and neointimal hyperplasia of overlap vs. non-overlap segments in drug-eluting stents 9-13 months after implantation: in vivo-assessment with optical coherence...

The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON) Compared with Different Polymer Based Drug-Eluting Stents in Real-World Coronary Artery Lesions.

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content